AI Revolutionizes Breast Cancer Treatment & EU Backs Rare Disease Drug - Life AI Weekly #21

Hi there,

Welcome to this week's edition of Life AI Weekly, where we delve into the latest advancements in Healthcare and Life Sciences AI. This week, we're highlighting some exciting developments in the field of drug discovery and healthcare technology. AI Identifies Drug Combos for Breast Cancer is making waves as researchers explore new ways to tackle this challenging disease. Meanwhile, Hemispherian AS's GLIX1 has received the EU Orphan Drug Designation, marking a significant step forward in the treatment of rare diseases.

In the realm of healthcare technology, DRUID AI has achieved Microsoft Certification for its healthcare AI solutions, showcasing the growing integration of AI in healthcare systems. Additionally, Corify Care has partnered with the Mayo Clinic to enhance cardiac care through AI, promising improved patient outcomes. Stay tuned as we continue to bring you the latest updates and breakthroughs in the world of AI-driven healthcare.

Matterworks Inc. has raised Series A funding to enhance machine intelligence in predictive biology, supporting the development of innovative solutions. Finnish venture capital firm Inventure VC has invested $5 million in Samphire Neuroscience to support the development of a brain device aimed at alleviating menstrual symptoms. John Snow Labs has acquired WiseCube to improve healthcare AI solutions by integrating biomedical knowledge graphs, advancing drug discovery and medical AI applications.

University of Cambridge researchers used AI to identify non-cancer drug combinations for breast cancer treatment. Hemispherian AS received EU Orphan Drug Designation for GLIX1 targeting glioma. 28bio launched the Nexon™ platform to enhance drug development for neurodegenerative disorders. Juvenescence acquired Ro5 to boost AI in drug discovery.

Queen Mary University of London has demonstrated that Research Grid's AI can automate clinical trial data entry, significantly reducing costs and errors. Freenome published results from the PREEMPT CRC study in JAMA, highlighting the effectiveness of its blood-based colorectal cancer test with nearly 49,000 participants. ThinkCyte launched MorphoScan Cloud, an AI-driven platform for cell morphology data analysis, enhancing data access and collaboration for VisionSort users. On June 5, 2025, Stand Up To Cancer and SandboxAQ announced a collaboration to enhance cancer treatment using advanced AI and data modeling tools.

DRUID AI has been recognized by Microsoft as the first Certified Software Provider for Healthcare AI in Central & Eastern Europe, Middle East and Africa, emphasizing its secure and scalable solutions on Microsoft Azure. The Cotiviti Client Conference 2025 in Salt Lake City brings together healthcare leaders to explore AI, interoperability, and cost reduction strategies in the healthcare system. On June 4, 2025, Frontline Group announced the launch of its vCON Program to enhance 211 call handling across the U.S. by transforming calls into structured data.